Last reviewed · How we verify

Hormone receptor positive malignant neoplasm of breast — Treatment Landscape & Competitive Intelligence

Hormone receptor positive malignant neoplasm of breast (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hormone receptor positive malignant neoplasm of breast, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Verzenio abemaciclib Eli Lilly Kinase inhibitor Cyclin-dependent kinases 4 and 6 (CDK4/CDK6) 2017-01-01
Kisqali ribociclib Novartis CDK4/6 inhibitor; aromatase inhibitor Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme 2017-01-01
Kisqali LEE011 Novartis Kinase Inhibitor Cyclin-dependent kinase 4 2017-01-01
Ibrance Palbociclib Pfizer CDK4/6 inhibitor Cyclin-dependent kinases 4 and 6 (CDK4/6) 2015-01-01
Afinitor everolimus Novartis Kinase Inhibitor [EPC] Serine/threonine-protein kinase mTOR 2009-01-01
Aromasin exemestane Pfizer Aromatase Inhibitor [EPC] Aromatase 1999-01-01
Femara letrozole Novartis AG Aromatase Inhibitor [EPC] aromatase enzyme 1997-07-25
Arimidex anastrozole AstraZeneca Aromatase inhibitor Aromatase enzyme 1995-12-27
Zoladex GOSERELIN ACETATE Tersera Gonadotropin Releasing Hormone Receptor Agonist Gonadotropin-releasing hormone receptor 1989-01-01
Zoladex goserelin Tersera Gonadotropin Releasing Hormone Receptor Agonist pituitary gonadotropin secretion 1989-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 3 drugs in Hormone receptor positive malignant neoplasm of breast
  2. Novartis · 3 drugs in Hormone receptor positive malignant neoplasm of breast
  3. Tersera · 2 drugs in Hormone receptor positive malignant neoplasm of breast
  4. AstraZeneca · 2 drugs in Hormone receptor positive malignant neoplasm of breast
  5. · 2 drugs in Hormone receptor positive malignant neoplasm of breast
  6. Central European Society for Anticancer Drug Research · 1 drug in Hormone receptor positive malignant neoplasm of breast
  7. Eli Lilly · 1 drug in Hormone receptor positive malignant neoplasm of breast
  8. Endo · 1 drug in Hormone receptor positive malignant neoplasm of breast
  9. Gulhane School of Medicine · 1 drug in Hormone receptor positive malignant neoplasm of breast
  10. Leticia Maria Defendi Barboza Marson · 1 drug in Hormone receptor positive malignant neoplasm of breast
  11. M.D. Anderson Cancer Center · 1 drug in Hormone receptor positive malignant neoplasm of breast
  12. National Center for Research Resources (NCRR) · 1 drug in Hormone receptor positive malignant neoplasm of breast

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hormone receptor positive malignant neoplasm of breast:

Cite this brief

Drug Landscape (2026). Hormone receptor positive malignant neoplasm of breast — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hormone-receptor-positive-malignant-neoplasm-of-breast. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing